A Phase 3 interventional study of Semaglutide and Placebo (semaglutide) in Diabetes Mellitus, Type 2 and Peripheral Arterial Disease, sponsored by Novo Nordisk A/S. Completed at 283 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment, is one of 9 that started in 2020, is one of 57 in phase 3, and was the 79th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Emory University · Sites in United States
Ages 65+ · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 14 · Phase 3 58 · Phase 4 40
First in 2007; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 792 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 104 across the 163 interventional studies. Of the 109 that completed or were terminated, 54 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 163 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 27 open now, 31 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 50th largest by enrollment of the 430 interventional ones that give a count, is one of 26 that started in 2020, is one of 187 in phase 3, and was the 510th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
14 of the studies testing semaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06461377The First Affiliated Hospital with Nanjing Medical UniversityThe Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 645 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for injection. Participants must inject it once a week into the stomach area, thigh, or upper arm, at any time of the day. The study will last for about 59 weeks. Participants will have 8 clinic visits and 1 phone call with the study doctor. At some clinic visits, participants will have blood tests. At some visits participants will also do a treadmill test to measure how far they can walk. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Symptomatic PAD with intermittent claudication corresponding to Fontaine stage IIa (Rutherford classification grade I, category 1 and 2) meeting all of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Semaglutide given in addition to standard-of-care treatment
Drug: Semaglutide
Placebo given in addition to standard-of-care treatment
Drug: Placebo (semaglutide)
Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
Change in Maximum Walking Distance on a Constant Load Treadmill Test
Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants continue on the treadmill after indicating onset of pain and should continue as long as possible until pain limits further activity. This distance is noted as the maximum walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
Time frame: Baseline (week 0), end of treatment (week 52)
Follow-up Change in Maximum Walking Distance on a Constant Load Treadmill Test
Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants continue on the treadmill after indicating onset of pain and should continue as long as possible until pain limits further activity. This distance is noted as the maximum walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, which-ever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
Time frame: Baseline (week 0), end of follow-up (week 57)
Change in Vascular Quality of Life Questionnaire-6 (VascuQoL-6) Score
Change in VascuQoL-6 score is presented. VascuQoL-6 is a peripheral artery disease-specific questionnaire with 6 items covering social, emotional, functional as well as pain- and symptom-related aspects of the patient´s overall quality of life. Each item has a 4-point response scale (where 1 = worst score and 4 = best score). The endpoint analysed is the total score (range: 6-24) generated by summing the scores from all items. A higher score indicates better health status. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Pain-free Walking Distance on a Constant Load Treadmill Test
Change in pain-free walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants are instructed to when pain starts in either leg and to continue on the treadmill without stopping at this stage. The distance walked is noted as the pain-free walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
Time frame: Baseline (week 0), end of treatment (week 52)
Follow-up Change in Pain-free Walking Distance on a Constant Load Treadmill Test
Change in pain-free walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants are instructed to when pain starts in either leg and to continue on the treadmill without stop-ping at this stage. The distance walked is noted as the pain-free walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
Time frame: Baseline (week 0), end of follow-up (week 57)
Change in Glycosylated Haemoglobin (HbA1c)
Change in HbA1c from baseline to week 52 in percentage-point is presented. The outcome measure is evaluated based on the on treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Body Weight
Change in body weight from baseline to week 52 in kilogram (kg) is presented. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Systolic Blood Pressure
Change in systolic blood pressure from baseline to week 52 is presented.The outcome measure is evaluated based on the on treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Total Cholesterol
Change in total cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Low-density Lipoprotein (LDL)-Cholesterol
Change in LDL-cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in High Density Lipoprotein (HDL)-Cholesterol
Change in HDL-cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Triglycerides
Change in Triglycerides from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Ankle-Brachial Index (ABI)
Change in ABI from baseline to week 52 is presented. ABI is calculated as a ratio of the higher ankle systolic pressure to the higher systolic pressure measured in both arms. ABI is measured at both left and right leg and the analysis endpoint is defined as the lower of the two indices. An ABI between 1.0 to 1.4 is considered the normal range. An ABI between 0.90 to 0.99 is considered borderline. An ABI less than 0.90 indicates peripheral artery disease (PAD). The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Screening (week -2), end of treatment (week 52)
Change in Toe-Brachial Index (TBI)
Change in TBI from baseline to week 52 is presented. TBI is calculated as a ratio of the toe systolic pressure to the higher systolic pressure measured in both arms. TBI is measured at both left and right leg and the analysis endpoint is defined as the lower of the two indices. A TBI range of above or equal to 0.7 is considered normal, whereas a TBI less than 0.7 is considered abnormal. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Screening (week -2), end of treatment (week 52)
Change in Walking Impairment Questionnaire (WIQ) Global Score
Change in WIQ global score from baseline to week 52 is presented. WIQ consists of three domains, speed, distance, and stair climbing, consisting of in total 14 questions. Each response is weighted based on the difficulty of the task. Domain scores are determined by dividing the weighted answers by the maximum possible weighted score and multiplying by 100. Global score is calculated as the mean of the three domain scores (ranged from 0% to 100%). A global score of 0% represents inabil-ity to perform any of the tasks and 100% represents no difficulty with any of the tasks. Higher scores indicate better walking ability and less impairment. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Short Form 36 (SF-36) Physical Functioning Domain
Change in SF-36 physical functioning domain from baseline to week 52 is presented. SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2 (acute version) questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). The 0-100 scale scores from the SF-36 were converted to norm-based scores (Range: 19.03 to 57.60) to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A positive change score indicates an improvement in participant health stats. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
Time frame: Baseline (week 0), end of treatment (week 52)
The trial was conducted at 129 sites in 21 countries.
| Milestone | Semaglutide | Placebo |
|---|---|---|
| Started | 396 | 396 |
| Full analysis set | 396 | 396 |
| Safety analysis set | 396 | 395 |
| Completed | 366 | 379 |
| Not completed | 30 | 17 |
| Withdrew: Withdrawal by subject | 18 | 12 |
| Withdrew: Lost to follow-up | 8 | 5 |
| Withdrew: Physician decision | 4 | 0 |
Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants continue on the treadmill after indicating onset of pain and should continue as long as possible until pain limits further activity. This distance is noted as the maximum walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
| Ratio of maximum walking distance | Semaglutide | Placebo |
|---|---|---|
| Change in Maximum Walking Distance on a Constant Load Treadmill Test | 1.21 (0.95 to 1.55) | 1.08 (0.86 to 1.36) |
Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants continue on the treadmill after indicating onset of pain and should continue as long as possible until pain limits further activity. This distance is noted as the maximum walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, which-ever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
| Ratio of maximum walking distance | Semaglutide | Placebo |
|---|---|---|
| Follow-up Change in Maximum Walking Distance on a Constant Load Treadmill Test | 1.16 (0.92 to 1.48) | 1.10 (0.87 to 1.40) |
Change in VascuQoL-6 score is presented. VascuQoL-6 is a peripheral artery disease-specific questionnaire with 6 items covering social, emotional, functional as well as pain- and symptom-related aspects of the patient´s overall quality of life. Each item has a 4-point response scale (where 1 = worst score and 4 = best score). The endpoint analysed is the total score (range: 6-24) generated by summing the scores from all items. A higher score indicates better health status. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
| Scores on a scale | Semaglutide | Placebo |
|---|---|---|
| Change in Vascular Quality of Life Questionnaire-6 (VascuQoL-6) Score | 2.0 (0.00 to 4.00) | 1.0 (-1.00 to 4.00) |
Change in pain-free walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants are instructed to when pain starts in either leg and to continue on the treadmill without stopping at this stage. The distance walked is noted as the pain-free walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
| Ratio of pain-free walking distance | Semaglutide | Placebo |
|---|---|---|
| Change in Pain-free Walking Distance on a Constant Load Treadmill Test | 1.21 (0.92 to 1.52) | 1.10 (0.86 to 1.44) |
Change in pain-free walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants are instructed to when pain starts in either leg and to continue on the treadmill without stop-ping at this stage. The distance walked is noted as the pain-free walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.
| Ratio of pain-free walking distance | Semaglutide | Placebo |
|---|---|---|
| Follow-up Change in Pain-free Walking Distance on a Constant Load Treadmill Test | 1.18 (0.92 to 1.59) | 1.10 (0.83 to 1.48) |
Change in HbA1c from baseline to week 52 in percentage-point is presented. The outcome measure is evaluated based on the on treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Percentage-point of HbA1c | Semaglutide | Placebo |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -0.8 ± 1.1 | 0.2 ± 1.1 |
Change in body weight from baseline to week 52 in kilogram (kg) is presented. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Kilogram (kg) | Semaglutide | Placebo |
|---|---|---|
| Change in Body Weight | -5.2 ± 4.8 | -1.2 ± 4.2 |
Change in systolic blood pressure from baseline to week 52 is presented.The outcome measure is evaluated based on the on treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Millimetre of mercury (mmHg) | Semaglutide | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure | -4 ± 15 | -1 ± 18 |
Change in total cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Ratio of total cholesterol | Semaglutide | Placebo |
|---|---|---|
| Change in Total Cholesterol | 0.96 ± 20.18 | 1.00 ± 19.88 |
Change in LDL-cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Ratio of LDL | Semaglutide | Placebo |
|---|---|---|
| Change in Low-density Lipoprotein (LDL)-Cholesterol | 0.99 ± 38.37 | 1.03 ± 42.27 |
Change in HDL-cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Ratio of HDL | Semaglutide | Placebo |
|---|---|---|
| Change in High Density Lipoprotein (HDL)-Cholesterol | 1.04 ± 15.95 | 0.99 ± 13.91 |
Change in Triglycerides from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Ratio of triglycerides | Semaglutide | Placebo |
|---|---|---|
| Change in Triglycerides | 0.80 ± 45.95 | 0.95 ± 41.73 |
Change in ABI from baseline to week 52 is presented. ABI is calculated as a ratio of the higher ankle systolic pressure to the higher systolic pressure measured in both arms. ABI is measured at both left and right leg and the analysis endpoint is defined as the lower of the two indices. An ABI between 1.0 to 1.4 is considered the normal range. An ABI between 0.90 to 0.99 is considered borderline. An ABI less than 0.90 indicates peripheral artery disease (PAD). The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Ratio of ABI | Semaglutide | Placebo |
|---|---|---|
| Change in Ankle-Brachial Index (ABI) | 1.06 ± 34.0 | 1.02 ± 19.6 |
Change in TBI from baseline to week 52 is presented. TBI is calculated as a ratio of the toe systolic pressure to the higher systolic pressure measured in both arms. TBI is measured at both left and right leg and the analysis endpoint is defined as the lower of the two indices. A TBI range of above or equal to 0.7 is considered normal, whereas a TBI less than 0.7 is considered abnormal. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Ratio of TBI | Semaglutide | Placebo |
|---|---|---|
| Change in Toe-Brachial Index (TBI) | 1.07 ± 34.4 | 1.04 ± 37.3 |
Change in WIQ global score from baseline to week 52 is presented. WIQ consists of three domains, speed, distance, and stair climbing, consisting of in total 14 questions. Each response is weighted based on the difficulty of the task. Domain scores are determined by dividing the weighted answers by the maximum possible weighted score and multiplying by 100. Global score is calculated as the mean of the three domain scores (ranged from 0% to 100%). A global score of 0% represents inabil-ity to perform any of the tasks and 100% represents no difficulty with any of the tasks. Higher scores indicate better walking ability and less impairment. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| %-point scores on a scale | Semaglutide | Placebo |
|---|---|---|
| Change in Walking Impairment Questionnaire (WIQ) Global Score | 9.48 ± 18.63 | 6.51 ± 20.53 |
Change in SF-36 physical functioning domain from baseline to week 52 is presented. SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2 (acute version) questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). The 0-100 scale scores from the SF-36 were converted to norm-based scores (Range: 19.03 to 57.60) to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A positive change score indicates an improvement in participant health stats. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).
| Scores on a scale | Semaglutide | Placebo |
|---|---|---|
| Change in Short Form 36 (SF-36) Physical Functioning Domain | 2.98 ± 7.32 | 1.52 ± 7.17 |
Collected over Until week 57. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide | 4/396 (1%) | 74/396 (18.7%) | 47/396 (11.9%) |
| Placebo | 9/395 (2.3%) | 78/395 (19.7%) | 24/395 (6.1%) |
| Event | Semaglutide | Placebo |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 3/396 | 5/395 |
| Peripheral arterial occlusive diseaseVascular disorders | 4/396 | 5/395 |
| PneumoniaInfections and infestations | 0/396 | 5/395 |
| Coronary artery diseaseCardiac disorders | 4/396 | 0/395 |
| Cerebral infarctionNervous system disorders | 3/396 | 3/395 |
| Peripheral ischaemiaVascular disorders | 1/396 | 3/395 |
| Acute kidney injuryRenal and urinary disorders | 3/396 | 0/395 |
| Angina unstableCardiac disorders | 3/396 | 2/395 |
| Coronary artery stenosisCardiac disorders | 3/396 | 0/395 |
| DiverticulitisInfections and infestations | 3/396 | 1/395 |
| Event | Semaglutide | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 30/396 | 21/395 |
| NauseaGastrointestinal disorders | 22/396 | 3/395 |
The full analysis set (FAS) included all randomised participants. All participants were analyzed according to the treatment to which they were assigned at randomisation
| Age, Continuous(Years) | Semaglutide | Placebo | Total |
|---|---|---|---|
| Mean | 66.2 ± 9.71 | 67.0 ± 8.96 | 66.6 ± 9.35 |
| Sex: Female, Male(Participants) | Semaglutide | Placebo | Total |
|---|---|---|---|
| Female | 107 | 88 | 195 |
| Male | 289 | 308 | 597 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 13 |
| Not Hispanic or Latino | 388 | 385 | 773 |
| Unknown or Not Reported | 1 | 5 | 6 |
| Race/Ethnicity, Customized(Participants) | Semaglutide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 131 | 109 | 240 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 4 | 4 | 8 |
| White | 259 | 279 | 538 |
| Other | 1 | 3 | 4 |
Showing the first 100 of 283 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Oct 2020 to primary completion in Jun 2024, 44 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 44 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide